Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on ...

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2022-12-08

Last Posted Date: 2022-12-08

Lead Sponsor: Germano Di Sciascio

Target Recruit Count: 50

Registration Number: NCT05643586

Locations: 🇧🇪
Aalst cardiovascular center, Aalst, Belgium

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2022-02-18

Last Posted Date: 2022-02-18

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 87

Registration Number: NCT05247385

Locations: 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, Sao Paulo, Brazil

Clopidogrel Monotherapy in Patients With High Bleeding Risk

Phase 4

Completed

Conditions: Bleeding Complications

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Tricagrelor

First Posted Date: 2022-02-03

Last Posted Date: 2024-02-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 98

Registration Number: NCT05223335

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Phase 4

Completed

Conditions: Coronary Artery Disease
Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Cangrelor

First Posted Date: 2020-12-16

Last Posted Date: 2024-03-20

Lead Sponsor: University of Florida

Target Recruit Count: 359

Registration Number: NCT04668144

Locations: 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: ticagrelor
Drug: Clopidogrel
Drug: aspirin
Drug: rivaroxaban

First Posted Date: 2019-07-05

Last Posted Date: 2023-04-26

Lead Sponsor: University of Florida

Target Recruit Count: 90

Registration Number: NCT04006288

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Phase 4

Completed

Conditions: Acute Coronary Syndrome (ACS)

Interventions: Drug: Prasugrel

First Posted Date: 2018-09-14

Last Posted Date: 2021-11-12

Lead Sponsor: Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

Target Recruit Count: 204

Registration Number: NCT03672097

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
Cheng Hsin General Hospital, Taipei, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

and more 7 locations

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Phase 4

Completed

Conditions: Aneurysm, Cerebral
Endovascular Procedures

Interventions: Drug: Aspirin
Drug: Prasugrel
Drug: Clopidogrel
Drug: Cilostazol

First Posted Date: 2018-07-10

Last Posted Date: 2022-04-27

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 198

Registration Number: NCT03581409

Locations: 🇰🇷
Seoul National Univeristy Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2018-04-06

Last Posted Date: 2020-09-16

Lead Sponsor: University of Florida

Target Recruit Count: 14

Registration Number: NCT03489863

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed

Conditions: Acute Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2018-03-06

Last Posted Date: 2020-02-26

Lead Sponsor: Collegium Medicum w Bydgoszczy

Target Recruit Count: 73

Registration Number: NCT03454841

Locations: 🇵🇱
Department of Cardiology, Wrocław Medical University, Wrocław, Dolnośląskie, Poland
🇵🇱
Department of Cardiology, Dr. A. Jurasz University Hospital, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Kujawsko-pomorskie, Poland

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

Not Applicable

Completed

Conditions: ST Elevation Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2018-02-15

Last Posted Date: 2019-06-10

Lead Sponsor: AORTICA Group

Target Recruit Count: 61

Registration Number: NCT03435133

Locations: 🇪🇸
Pedro Dorado, Salamanca, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy